

1 Robert V. Prongay (SBN 270796)  
 2 Pavithra Rajesh (SBN 323055)  
**3 GLANCY PRONGAY & MURRAY LLP**  
 4 1925 Century Park East, Suite 2100  
 Los Angeles, California 90067  
 Telephone:(310) 201-9150  
 5 Facsimile: (310) 201-9160  
 6 Email: rprongay@glancylaw.com  
 prajesh@glancylaw.com

7  
 8 *Attorneys for Lead Plaintiffs Ervin Derr*  
*and Peter Shoemaker*

9 [Additional Counsel on Signature Page]

10 **UNITED STATES DISTRICT COURT**  
 11 **SOUTHERN DISTRICT OF CALIFORNIA**

13 ERVIN DERR, and PETER  
 14 SHOEMAKER, Individually and on  
 15 Behalf of All Others Similarly Situated,

16 Plaintiff,

17 v.

18 RA MEDICAL SYSTEMS, INC.,  
 DEAN IRWIN, ANDREW JACKSON,  
 19 MELISSA BURSTEIN, MARTIN  
 BURSTEIN, RICHARD HEYMANN,  
 MAURICE BUCHBINDER, MARTIN  
 20 COLOMBATTO, RICHARD MEJIA,  
 JR., MARK E. SAAD, and WILLIAM  
 21 ENQUIST, JR.,

22 Defendants.

Case No. 3:19-cv-01079-LAB-AHG  
**SECOND AMENDED COMPLAINT**  
 The Hon. Larry Alan Burns

23  
 24  
 25  
 26  
 27  
 28

**TABLE OF CONTENTS**

1

2 I. INTRODUCTION..... 1

3

4 II. JURISDICTION AND VENUE..... 6

5 III. PARTIES..... 6

6 IV. PLAINTIFFS PURCHASED RA MEDICAL SHARES PURSUANT OR

7 TRACEABLE TO THE REGISTRATION STATEMENT ..... 11

8 V. CLASS ACTION ALLEGATIONS..... 13

9 VI. BACKGROUND..... 14

10 A. Company Overview ..... 14

11 B. Ra Medical Must Comply With Strict FDA Regulations..... 15

12 1. FDA Limits The Intended Use Of DABRA To Treat Certain

13 Forms Of PAD ..... 16

14 2. Ra Medical Can Only Market DABRA For Its Intended Use.... 16

15 3. If Ra Medical Initiates Any Correction Or Recall Of DABRA, It

16 Must Notify The FDA ..... 17

17 4. Ra Medical Must Notify The FDA If DABRA Malfunctions.... 17

18 C. Unbeknownst To Investors, The FDA Warned Ra Medical Prior To

19 The IPO That The Company Was Improperly Engaging In Off-Label

20 Marketing ..... 18

21 D. Before The IPO, Ra Medical Denied Allegations Of Off-Label

22 Marketing In Connection With A Dispute With Strata Skin Sciences,

23 Inc..... 20

24 VII. SUMMARY OF DEFENDANTS’ VIOLATIONS OF THE SECURITIES

25 ACT ..... 23

26 A. The Company Completed The IPO..... 23

27

28

1 B. The Registration Statement Contained Untrue Statements Of Material  
2 Facts And/Or Omitted To State Material Facts Required To Be Stated  
3 Therein Or Necessary To Make The Statements Therein Not  
4 Misleading..... 23

5 C. Defendants Admit That Statements In The Registration Statement Were  
6 Untrue And/Or Omitted Material Information ..... 26

7 D. Investors Who Bought Ra Medical Stock Pursuant And/Or Traceable  
8 To The IPO Suffered Substantial Losses ..... 28

9 VIII. SUMMARY OF DEFENDANTS’ VIOLATIONS OF THE EXCHANGE  
10 ACT ..... 29

11 A. When Ra Medical Went Public, Its DABRA Catheter Presented Strong  
12 Prospects For Future Sales Growth..... 29

13 B. After The IPO, Ra Medical Touts Positive Progress In Expanding Its  
14 Salesforce And Denies Claims Of Off-Label Marketing ..... 30

15 C. The Truth Begins To Emerge As Ra Medical Discloses Manufacturing  
16 Problems, While Defendants Falsely Claim That The Problems Have  
17 Been Fixed And Omit Other Material Information ..... 31

18 1. Ra Medical Falsely Claims That “Production Limitations”  
19 Stemming From Increased Demand Negatively Impacted Fourth  
20 Quarter 2018 Sales..... 31

21 2. Ra Medical Falsely And/Or Misleadingly Assures Investors That  
22 Problems With Catheter Production Have Been Resolved ..... 33

23 D. The Truth Further Emerges As Defendants Admit That DABRA  
24 Catheters Failed To Calibrate, Resulting In A Product Recall, And That  
25 Ra Medical Engaged In Off-Label Marketing..... 35

26 1. Ra Medical Admits To The Product Issues And Its Audit  
27 Committee Launches An Investigation Into An Anonymous  
28 Complaint..... 35

2. Obscuring That It Had Been Engaged In A Covert Recall For  
Months, Ra Medical Announces A Voluntary Recall..... 38

3. The Audit Committee Investigation Reports Its Findings..... 39

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

- 4. Ra Medical Discloses A Criminal Investigation And Deficiencies In Its Internal Controls..... 41
- IX. RA MEDICAL ADMITS THAT THE REGISTRATION STATEMENT AND STATEMENTS MADE DURING THE CLASS PERIOD WERE MATERIALLY FALSE AND/OR MISLEADING AND/OR OMITTED MATERIAL FACTS ..... 42
  - A. The Audit Committee Investigation Findings ..... 42
  - B. Former Ra Medical Employees Corroborate The Audit Committee’s Findings..... 44
    - 1. Ra Medical Was Experiencing Calibration Issues With The DABRA Catheter At The Time Of The IPO ..... 44
    - 2. Ra Medical Engaged In A Covert Product Recall..... 45
    - 3. Sales Representatives Were Directed To Market DABRA For Off-Label Uses..... 46
    - 4. Ra Medical Lacked An Adequate System to Document Expenses ..... 48
    - 5. An Injury During The 2017 Pivotal Study Was Not Reported To The FDA ..... 48
  - C. Recall Notice Suggests That Ra Medical Initiated The Recall Seven Months Before The IPO ..... 49
  - D. Ra Medical Failed To Timely File Three MDRs..... 49
  - E. Ra Medical Settles DOJ Investigation Into Off-Label Marketing and Kickbacks to Physicians..... 50
- X. DEFENDANTS’ FALSE AND/OR MISLEADING STATEMENTS AND/OR OMISSIONS ..... 51
  - A. False And/Or Misleading Statements And/Or Omissions Made In Connection With The IPO..... 51
    - 1. The Registration Statement And Roadshow Materials Touted Ra Medical’s Manufacturing Facility ..... 51

1           2.     The Registration Statement Warned Of A Hypothetical Product  
2           Recall But Omitted Quality-Related Issues It Was Already  
3           Experiencing ..... 54  
4           3.     The Registration Statement And Roadshow Materials Omitted  
5           To Disclose That Ra Medical Engaged In Off-Label Marketing  
6           To Increase DABRA Sales ..... 54  
7           4.     The Registration Statement And Roadshow Materials Omitted  
8           To Disclose That Ra Medical Engaged In Potential Bribery To  
9           Increase DABRA Sales..... 56  
10          5.     The Registration Statement And Roadshow Materials Omitted A  
11          Patient’s Injury Experienced During The 2017 Pivotal Study For  
12          DABRA ..... 59  
13          B.     False And/Or Misleading Statements And/Or Omissions In Ra  
14          Medical’s Code of Ethics and Conduct ..... 60  
15          C.     False And/Or Misleading Statements And/Or Omissions Made In  
16          Connection With The Announcement Of Ra Medical’s Third Quarter  
17          2018 Financial Results ..... 62  
18          D.     False And/Or Misleading Statements And/Or Omissions Made At  
19          Biotech Showcase On January 8, 2019..... 70  
20          E.     False And/Or Misleading Statements And/Or Omissions Made In  
21          Connection With The Announcement Of Ra Medical’s Fourth Quarter  
22          2018 Financial Results ..... 71  
23          F.     False And/Or Misleading Statements And/Or Omissions Made In  
24          Connection With The Announcement Of Ra Medical’s First Quarter  
25          2019 Financial Results ..... 81  
26          G.     False And/Or Misleading Statements And/Or Omissions Regarding  
27          The Product Recall..... 88  
28          XI.    LOSS CAUSATION ..... 89  
29          XII.   POST-CLASS PERIOD EVENTS..... 93  
30          XIII.   ADDITIONAL SCIENTER ALLEGATIONS ..... 94  
31          XIV.   UNDISCLOSED ADVERSE FACTS ..... 97

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.